Genmab — Februar 2019
-
ja - vi savner noget validering
-
New trial by Incyte corporation: INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma - INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
-
-
-
we were told we would get "an early peak at data from Griffin" ; the trial shows it reached the primary completion date in january. https://clinicaltrials.gov/ct2/history/NCT02874742?A=26&B=27&C=merged
-
Abbvie comes to the multiple myeloma party late / JNJ-7957
-
ok, so JNJ actually states "Splitting the first dose of DARZALEX over two consecutive days effectively reduced the duration of the first infusion …" https://www.jnj.com/u-s-fda-approves-darzalex-daratumumab-split-dosing-regimen
-
Har dette nye fase 3 været omtalt https://clinicaltrials.gov/ct2/show/NCT03836014?term=daratumumab&draw=2&rank=72
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind